Boston Scientific Corporation

XTRA:BSX Stock Report

Market Cap: €125.8b

Boston Scientific Valuation

Is BSX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BSX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BSX (€85.5) is trading below our estimate of fair value (€85.68)

Significantly Below Fair Value: BSX is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BSX?

Key metric: As BSX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BSX. This is calculated by dividing BSX's market cap by their current earnings.
What is BSX's PE Ratio?
PE Ratio74.3x
EarningsUS$1.79b
Market CapUS$133.31b

Price to Earnings Ratio vs Peers

How does BSX's PE Ratio compare to its peers?

The above table shows the PE ratio for BSX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20.6x
SHL Siemens Healthineers
28.3x14.2%€55.1b
AFX Carl Zeiss Meditec
25.2x16.3%€5.1b
EUZ Eckert & Ziegler
21.9x5.9%€787.5m
DRW3 Drägerwerk KGaA
7.1x2.0%€791.0m
BSX Boston Scientific
74.3x23.2%€133.3b

Price-To-Earnings vs Peers: BSX is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the peer average (20.6x).

Price to Earnings Ratio vs Industry

How does BSX's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BSX 74.3xIndustry Avg. 28.9xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BSX is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the European Medical Equipment industry average (28.9x).

Price to Earnings Ratio vs Fair Ratio

What is BSX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BSX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio74.3x
Fair PE Ratio39.7x

Price-To-Earnings vs Fair Ratio: BSX is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the estimated Fair Price-To-Earnings Ratio (39.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BSX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€85.50
€91.55
+7.1%
6.4%€103.82€78.34n/a31
Nov ’25€77.50
€88.96
+14.8%
6.8%€101.90€73.38n/a31
Oct ’25€76.00
€79.06
+4.0%
5.4%€90.34€70.47n/a32
Sep ’25€74.00
€78.49
+6.1%
5.4%€90.04€70.23n/a32
Aug ’25€69.50
€80.57
+15.9%
5.5%€92.50€72.15n/a31
Jul ’25€71.50
€77.02
+7.7%
6.3%€84.17€65.46n/a31
Jun ’25€69.00
€75.78
+9.8%
6.1%€83.11€64.64n/a31
May ’25€67.50
€75.57
+12.0%
5.7%€84.18€65.47n/a32
Apr ’25€63.56
€65.68
+3.3%
5.8%€74.16€55.85n/a31
Mar ’25€61.80
€65.79
+6.5%
6.6%€74.75€50.75n/a30
Feb ’25€59.24
€64.10
+8.2%
7.5%€74.52€50.60n/a30
Jan ’25€51.40
€56.00
+9.0%
7.1%€69.99€47.72n/a30
Dec ’24€51.56
€54.93
+6.5%
4.9%€61.22€47.97n/a30
Nov ’24€48.53
€56.77
+17.0%
4.8%€63.41€49.69€77.5030
Oct ’24€50.22
€57.02
+13.5%
4.5%€61.89€51.58€76.0030
Sep ’24€49.70
€55.34
+11.3%
3.9%€59.16€50.84€74.0030
Aug ’24€46.99
€54.21
+15.4%
5.8%€58.20€40.92€69.5031
Jul ’24€49.53
€53.27
+7.6%
5.6%€58.65€41.24€71.5030
Jun ’24€48.11
€53.49
+11.2%
5.5%€57.62€41.82€69.0029
May ’24€47.61
€51.88
+9.0%
6.3%€56.51€41.02€67.5027
Apr ’24€45.99
€48.79
+6.1%
6.1%€54.43€41.51€63.5627
Mar ’24€43.77
€49.02
+12.0%
6.3%€55.07€42.00€61.8027
Feb ’24€42.96
€46.84
+9.0%
6.0%€50.98€40.96€59.2426
Jan ’24€43.25
€46.94
+8.5%
5.9%€51.90€42.46€51.4028
Dec ’23€43.61
€46.93
+7.6%
4.4%€51.13€43.41€51.5626
Nov ’23€43.34
€48.80
+12.6%
4.9%€53.17€45.15€48.5326

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Universal Health Services

US$13.1b

Through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities.

UHS

US$186.00

7D

-5.6%

1Y

50.0%

Shandong Weigao Group Medical Polymer

HK$20.7b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-6.2%

1Y

-37.3%

CVS Health

US$70.5b

Provides health solutions in the United States.

CVS

US$53.28

7D

3.9%

1Y

-14.3%